Itch-Focused Creabilis Finally Secures Its Future Through US Sale
Executive Summary
Creabilis has finally secured the future of its Phase III-ready psoriatic itch candidate CT327 – through a sale of the company to young US firm Sienna Biopharmaceuticals.
You may also be interested in...
Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.
Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus
Keen to make up for lost time, dermatology specialist Creabilis Ltd is using positive Phase IIb data to advance its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, on to Phase III trials in psoriasis patients which, if successful, should open the way for regulatory filing in mid-2018 for a condition where there is no approved standard of care.
Phase IIb data scratch the itch for Creabilis
Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.